Methotrexate Accord Healthcare

Methotrexate, the active ingredient in Methotrexate Accord Healthcare, is an antimetabolite (folate antagonist) presented as a sterile injectable solution for intra‑arterial, intramuscular, and intravenous use. It is employed to treat autoimmune disorders and certain malignancies in adult and pediatric patients. GNH USA supplies Methotrexate Accord Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Methotrexate acts on rapidly dividing cells and immune pathways, providing disease‑modifying effects across several therapeutic areas. - Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriasis: diminishes skin lesions by inhibiting keratinocyte proliferation. - Acute lymphoblastic leukemia: eradicates malignant lymphoblasts through folate pathway blockade. - Osteosarcoma: impedes tumor growth by disrupting DNA synthesis. - Gestational trophoblastic disease: induces remission by targeting proliferative trophoblastic tissue.

Methotrexate may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset occurring shortly after administration. - Oral ulcers: painful sores on the mucous membranes of the mouth. - Fatigue: persistent tiredness not relieved by rest. - Alopecia: temporary hair thinning or loss.

Serious or Rare Side Effects: - Bone marrow suppression: leading to anemia, leukopenia or thrombocytopenia. - Severe hepatotoxicity: marked elevation of liver enzymes or fibrosis. - Pulmonary fibrosis: progressive scarring of lung tissue causing breathlessness. - Anaphylactic reaction: acute hypersensitivity requiring immediate medical intervention.

Prior to initiating therapy, clinicians should assess baseline laboratory values and patient risk factors. - Monitor blood counts: perform regular complete blood count testing to detect marrow suppression. - Assess liver function: check hepatic enzymes before and during treatment. - Evaluate renal function: adjust dosing in patients with impaired clearance. - Avoid use in pregnancy: teratogenic risk mandates contraception for women of child‑bearing potential. - Counsel on infection risk: advise patients to report fever or signs of infection promptly. - Store at ambient temperature: keep in original container, protect from moisture and light.

Methotrexate's efficacy and toxicity can be altered by concomitant medicines.

Major Interactions (Avoid): - NSAIDs: increase methotrexate serum concentrations and risk of renal toxicity. - Trimethoprim‑sulfamethoxazole: synergistic myelosuppression leading to severe cytopenias.

Moderate Interactions (Monitor Closely): - Azathioprine: additive immunosuppression may heighten infection risk. - Warfarin: potentiates anticoagulant effect, requiring INR monitoring. - Oral contraceptives: may reduce methotrexate clearance, necessitating dose adjustment.